JP2009535422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535422A5 JP2009535422A5 JP2009510011A JP2009510011A JP2009535422A5 JP 2009535422 A5 JP2009535422 A5 JP 2009535422A5 JP 2009510011 A JP2009510011 A JP 2009510011A JP 2009510011 A JP2009510011 A JP 2009510011A JP 2009535422 A5 JP2009535422 A5 JP 2009535422A5
- Authority
- JP
- Japan
- Prior art keywords
- implant
- biodegradable
- vasoactive
- vasodilator
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 claims 17
- 230000002227 vasoactive effect Effects 0.000 claims 5
- 229940124549 vasodilator Drugs 0.000 claims 5
- 239000003071 vasodilator agent Substances 0.000 claims 5
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 230000004438 eyesight Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000002040 relaxant effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000050 smooth muscle relaxant Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000002550 vasoactive agent Substances 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/417,420 US20070260203A1 (en) | 2006-05-04 | 2006-05-04 | Vasoactive agent intraocular implant |
| PCT/US2007/067883 WO2007130945A1 (en) | 2006-05-04 | 2007-05-01 | A sustained-release intraocular implant comprising a vasoactive agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013170156A Division JP2014014694A (ja) | 2006-05-04 | 2013-08-20 | 血管拡張薬を含有する持続放出性眼内インプラント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535422A JP2009535422A (ja) | 2009-10-01 |
| JP2009535422A5 true JP2009535422A5 (enExample) | 2010-06-24 |
Family
ID=38508941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510011A Pending JP2009535422A (ja) | 2006-05-04 | 2007-05-01 | 血管作動薬を含有する持続放出性眼内インプラント |
| JP2013170156A Pending JP2014014694A (ja) | 2006-05-04 | 2013-08-20 | 血管拡張薬を含有する持続放出性眼内インプラント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013170156A Pending JP2014014694A (ja) | 2006-05-04 | 2013-08-20 | 血管拡張薬を含有する持続放出性眼内インプラント |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070260203A1 (enExample) |
| EP (1) | EP2026764B1 (enExample) |
| JP (2) | JP2009535422A (enExample) |
| AU (1) | AU2007248143B2 (enExample) |
| BR (1) | BRPI0711311A2 (enExample) |
| CA (1) | CA2651300C (enExample) |
| DK (1) | DK2026764T3 (enExample) |
| WO (1) | WO2007130945A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| WO2002043785A2 (en) | 2000-11-29 | 2002-06-06 | Oculex Pharmaceuticals, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| JP5330401B2 (ja) | 2007-11-08 | 2013-10-30 | アリメラ・サイエンシーズ，インコーポレーテッド | 眼のための埋め込み装置、及びその装置を備えるキット |
| DE102008040786A1 (de) * | 2008-07-28 | 2010-02-04 | Biotronik Vi Patent Ag | Biokorrodierbares Implantat mit einer Beschichtung enthaltend eine wirkstofftragende Polymermatrix |
| US20100204325A1 (en) * | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| CA2762536C (en) | 2009-05-18 | 2019-05-21 | Dose Medical Corporation | Drug eluting ocular implant |
| US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
| EP2571526B1 (en) | 2010-05-17 | 2019-03-13 | Novaer Holdings, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US8715713B2 (en) | 2011-04-29 | 2014-05-06 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| WO2013049107A2 (en) * | 2011-09-27 | 2013-04-04 | The Regents Of The University Of Colorado, A Body Corporate | Intraocular encapsulation of oxygenic bacteria |
| AU2014216112B2 (en) * | 2013-02-15 | 2019-02-21 | Allergan, Inc. | Sustained drug delivery implant |
| US20150342875A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| KR20210013088A (ko) | 2018-05-24 | 2021-02-03 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| KR20210013089A (ko) | 2018-05-24 | 2021-02-03 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| WO2020120480A1 (en) * | 2018-12-10 | 2020-06-18 | University Of Copenhagen | Vasodilators for use in the treatment of a retinal ischemic disorder |
| GB2601922B (en) | 2019-06-27 | 2024-04-24 | Layerbio Inc | Ocular device drub delivery systems |
| IL292350A (en) | 2019-10-30 | 2022-06-01 | Perfuse Therapeutics Inc | Treatment of ocular diseases using endothelin receptor antagonists |
| US12226452B2 (en) * | 2020-03-04 | 2025-02-18 | The Schepens Eye Research Institute, Inc. | Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| AU2022264438A1 (en) * | 2021-04-30 | 2023-11-23 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| BR112023022705A2 (pt) * | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| JPS58126435U (ja) * | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ｔｔｌオ−トストロボ用絞り制御回路 |
| US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US6306426B1 (en) * | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
| AU738338B2 (en) * | 1997-08-11 | 2001-09-13 | Allergan, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| WO2002043785A2 (en) * | 2000-11-29 | 2002-06-06 | Oculex Pharmaceuticals, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| EP1347980A4 (en) * | 2000-12-01 | 2005-02-09 | Osi Pharm Inc | RECEPTOR SPECIFIC COMPOUNDS OF ADENOSINE-A1, -A2A, AND-A3 AND USES THEREOF |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US20050203542A1 (en) * | 2002-09-18 | 2005-09-15 | Allergan, Inc. | Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events |
| US6899717B2 (en) * | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
| US7468065B2 (en) * | 2002-09-18 | 2008-12-23 | Allergan, Inc. | Apparatus for delivery of ocular implants |
| US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| WO2005107708A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
| EP1804751A2 (en) * | 2004-10-04 | 2007-07-11 | QLT USA, Inc. | Ocular delivery of polymeric delivery formulations |
| CA2615360A1 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Formulation and method for administration of ophthalmologically active agents |
-
2006
- 2006-05-04 US US11/417,420 patent/US20070260203A1/en not_active Abandoned
-
2007
- 2007-05-01 AU AU2007248143A patent/AU2007248143B2/en not_active Ceased
- 2007-05-01 CA CA2651300A patent/CA2651300C/en active Active
- 2007-05-01 DK DK07761644.9T patent/DK2026764T3/en active
- 2007-05-01 BR BRPI0711311-0A patent/BRPI0711311A2/pt not_active IP Right Cessation
- 2007-05-01 JP JP2009510011A patent/JP2009535422A/ja active Pending
- 2007-05-01 EP EP07761644.9A patent/EP2026764B1/en not_active Not-in-force
- 2007-05-01 WO PCT/US2007/067883 patent/WO2007130945A1/en not_active Ceased
-
2013
- 2013-08-20 JP JP2013170156A patent/JP2014014694A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535422A5 (enExample) | ||
| JP2008540552A5 (enExample) | ||
| CN111743878B (zh) | 用于眼科应用和/或其它应用的组合物以及方法 | |
| TWI542338B (zh) | 用於活性劑之控制釋放的眼用裝置 | |
| JP5696121B2 (ja) | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
| AU2013256092B2 (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| JP6100782B2 (ja) | 緑内障および高眼圧症を治療するための活性剤の徐放送達 | |
| US9931306B2 (en) | Methods and biocompatible compositions to achieve sustained drug release in the eye | |
| JP2007535539A5 (enExample) | ||
| WO2011109384A2 (en) | Biodegradable polymers for lowering intraocular pressure | |
| JP2012521997A5 (enExample) | ||
| JP2016513109A (ja) | 持続型薬物送達インプラント | |
| TW200826943A (en) | Intraocular drug delivery systems | |
| JP2007535535A5 (enExample) | ||
| JP2023120431A (ja) | 眼の症状の治療のための硝子体内薬物送達システム | |
| AR048646A1 (es) | Implante intraocular o intravitreo biodegradable que comprende un inhibidor de tirosina quinasa y un polimero biodegradable, metodo para producirlo y medicamento correspondiente | |
| CN114980861A (zh) | 缓释药物递送装置 | |
| JP2007535564A5 (enExample) | ||
| US12115246B2 (en) | Compositions and methods for ophthalmic and/or other applications | |
| TW202345803A (zh) | 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 | |
| AU2019245436B2 (en) | Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment | |
| HK40039407A (en) | Compositions and methods for ophthalmic and/or other applications | |
| HK40039406A (en) | Compositions and methods for ophthalmic and/or other applications | |
| CN118591369A (zh) | 挤出式眼部插入物或植入物及其方法 | |
| HK40118700A (zh) | 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法 |